By ZH Sailing
For decades, China was often treated as a late-stage market in the global pharmaceutical industry — a place where products were introduced after approvals in the United States or Europe.
That model is now quietly changing.
A recent move by Japan-based ophthalmology company Santen Pharmaceutical reflects a broader shift:
China is no longer being positioned at the end of the global drug development pipeline — but increasingly at its center.
From “Late Entry” to “Early Integration”
Santen’s latest strategy is straightforward but significant:
Integrate China earlier into global development and registration plans.
This adjustment may appear technical, but its implications are structural.
Traditionally:
- Clinical trials were conducted primarily in Western markets
- Regulatory approvals followed a sequential, region-by-region process
- China often entered at a later commercialization stage
Now, that sequence is being reconfigured.
By bringing China into:
- Early-stage clinical design
- Data generation
- Regulatory planning
pharmaceutical companies are effectively acknowledging that:
China is no longer just a market — it is part of the innovation system.
The Demand Story: Scale Meets Urgency
One of the strongest drivers behind this shift is demand — not just in size, but in structure.
China’s ophthalmology market illustrates this clearly:
- Over 50% of young people are affected by myopia
- Chronic eye conditions such as glaucoma and dry eye disease are rising
- Aging demographics are increasing demand for retinal treatments
This creates a unique combination:
👉 Massive patient base
👉 Diverse clinical needs
👉 Long-term treatment cycles
For global pharma, this is not just a commercial opportunity — it is a data-rich environment that can shape product development itself.
A More Complex — but More Valuable — Market
However, entering China today is not simply about scale.
Companies must navigate:
- Regulatory feasibility
- Pricing and reimbursement systems
- Hospital access channels
- Real-world clinical practice variations
This complexity is precisely why early integration matters.
Instead of adapting products after approval, companies are now designing therapies that are:
- Clinically relevant to Chinese patients
- Compatible with local healthcare systems
- More likely to achieve faster adoption
In this sense, localization is no longer an operational step —
it is becoming a core strategic capability.
Partnership as a New Default Model
Another notable shift is the growing importance of local partnerships.
Santen’s collaboration with a Chinese biotech firm is not an isolated case. It reflects a broader industry trend:
Global expertise + Local innovation
This model offers several advantages:
- Faster clinical development through local networks
- Better understanding of patient pathways
- Stronger regulatory alignment
- More efficient commercialization
It also signals a deeper change:
Foreign companies are no longer operating “in parallel” to China’s pharmaceutical ecosystem —
they are becoming part of it.
Technology and Data: Quiet Enablers
While not always visible, digital tools and data integration are playing an increasingly important role.
Companies are leveraging:
- Real-world evidence
- Digital trial management
- Data-driven regulatory submissions
to improve both speed and precision.
In China, where:
- Patient volumes are large
- Digital health adoption is high
these capabilities can significantly shorten development cycles.
This further reinforces China’s role as a strategic innovation environment, not just a sales destination.
The Policy Backdrop: Predictability Matters
Behind these corporate decisions lies an equally important factor: policy evolution.
China’s healthcare and regulatory systems have become:
- More structured
- More transparent
- More aligned with international standards
Initiatives such as “Healthy China 2030” also signal long-term commitment to:
- Expanding healthcare access
- Encouraging innovation
- Improving treatment quality
For global pharmaceutical companies, this creates something critical:
Predictability.
And in capital-intensive industries like pharma, predictability often matters more than speed.
What This Signals
Taken together, these developments point to a broader transformation.
🟢 Then:
- China as a late-stage commercial market
🔵 Now:
- China as a core node in global drug development
This shift carries several implications:
- Product strategies will increasingly be global-from-day-one, including China
- Clinical trials will become more geographically integrated
- Competition will intensify as both global and domestic players innovate simultaneously
- Patients in China may gain earlier access to cutting-edge treatments
The Bigger Picture
The pharmaceutical industry is not alone in this transition.
Across sectors, multinational companies are reassessing China’s role in their global strategies — not just as a market, but as:
- A source of demand
- A center of innovation
- A partner in development
Healthcare, however, makes this shift particularly visible because of its direct link to:
human need, public policy, and long-term investment cycles.
Final Thought
Santen’s strategy is not simply about expanding in China.
It reflects a deeper realization shared by a growing number of global companies:
To compete globally, you increasingly need to be integrated with China — not just present in it.
As this shift accelerates, the question for multinational pharma is no longer:
“When do we enter China?”
But rather:
“How early do we build China into our global strategy?”